Research
Hormonal
GLP-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists provide clinically meaningful weight loss of approximately 15%–21% at 68–72 weeks in major trials.
Practitioners can expect significant weight loss in patients using GLP-1 therapies over the specified duration.
StrongSupportsmedium confidence
GLP-1-based therapies provide clinically meaningful weight loss (approximately 15%–21% at 68–72 weeks in major trials).
Why this rating
Based on major trials mentioned in the abstract.
Source
Reframing obesity as a chronic, multifactorial disease: Clinical implications of GLP-1–based therapies
Roopesh Jain · Advances in Biomedical and Health Sciences · 2026
DOI 10.4103/abhs.abhs_94_25
review · n=17604
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →